You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Autonomous Broad Spectrum Environmental Sentinels

    SBC: NEVADA NANOTECH SYSTEMS, INC.            Topic: A13AT017

    We propose a platform for aerial environmental monitoring based on the integration of two advanced technologies for the first time: a lightweight, flying robotic platform capable of hovering and swarming, and a compact, low-power chemical sensor platform called the Molecular Property Spectrometer (MPS): a robust, low-cost, silicon-chip-based micro-electro-mechanical system (MEMS) that has been use ...

    STTR Phase I 2014 Department of DefenseArmy
  2. Dual-Mode Continuous-Wave Ladar and Optical Communications System

    SBC: Bridger Photonics, Inc.            Topic: A12089

    Because the data products generated by modern imaging ladar systems are inherently large in information content, there is currently a severe bottleneck in the communications of these products to end users, particularly when full-waveform recovery is desired. During the Phase I effort, Bridger demonstrated that their 3D imaging system architecture was ideally suited for seamless integration of high ...

    SBIR Phase II 2014 Department of DefenseArmy
  3. The Most Efficient (TME) Cold Chain Container for Blood

    SBC: RESODYN CORPORATION            Topic: A12113

    Resodyn Corporation proposes to develop a novel cold chain system with a Lifetime Warranty (20+ years) for the vacuum container.The container is composed of a passive energy efficient system for transporting blood and pharmaceuticals in hostile environments for up to three days.Capacity is four unit blood transfusion bags.Energy efficiency is possible by the novel shape and super insulating qualit ...

    SBIR Phase II 2014 Department of DefenseArmy
  4. Glycoengineered baculoviruses for the production of more efficacious influenza va

    SBC: Glycobac, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Vaccination significantly reduces morbidity and mortality caused by annual influenza epidemics. Traditionally, influenza vaccines have been manufactured using adapted influenza virus grown in eggs. However, this methodsuffers from inherent disadvantages such as slow production and allergenic egg proteins in the final product. To avoid these drawbacks, new vacci ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. On Site Mercury Remediation via Activated Fly Ash

    SBC: POLLUTION CONTROL TECHNOLOGIES, LLC            Topic: NIEHS

    DESCRIPTION (provided by applicant): Coal-fired power plants and burners are vital drivers of the U.S. economy-but they unfortunately produce substantial amounts of mercury (Hg) that are seriously harmful to human health, particularly linked to damages ofthe nervous system. Healthcare costs due to Hg exposure are estimated to be in the billions of dollars annually. New mercury-emission regulations ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Engineering cells for concurrent protein drug biosynthesis and polysialylation

    SBC: Glycobac, LLC            Topic: NIGMS

    Project Summary / Abstract Therapeutic proteins, or biologics, represent a 100 billion market that includes drugs such as antibodies, hormones, and many others. The clinical efficacy of biologics is critically determined by their circulating half-lives.Hence, various methods have been developed to increase their circulating half-lives by reducing clearance rates. This is commonly achieved by che ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. A NOVEL TARGETED DELIVERY SYSTEM FOR CANCER TREATMENT AND DIAGNOSIS

    SBC: ENDURX PHARMACEUTICALS INC            Topic: NCI

    DESCRIPTION (provided by applicant): Glioblastoma multiforme (GBM) or glioblastoma, is the most common and aggressive malignant primary brain tumor in humans. An effective treatment that increases patient survival would represent a significant advance inthe field, and provide a desperately needed new therapy for this deadly disease. EnduRx is focused on the development of new, targeted systems f ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Point-of-care immunoassay for early diagnosis of pertussis

    SBC: DXDISCOVERY INC            Topic: NIAID

    DESCRIPTION provided by applicant Pertussis is a serious and potentially life threatening respiratory disease caused by the bacterium Bordetella pertussis Worldwide million people become ill with pertussis each year and of these patients die Despite high vaccine coverage in the United States there were still over pertussis cases reported in the U S in Rapid diagn ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Co-axial Microinjection System for Freezing and Biopsy of Early Embryos

    SBC: GENESEARCH, INC.            Topic: 100

    DESCRIPTION provided by applicant The Dracula Pipette is a co axial embryo microinjection tool with the injection pipette presented from inside the holding pipette Double nested tips seal against the surface of the spherical embryo when a vacuum is applied in the space between them This allows a portion of the nearside surface of an embryo to be held by vacuum while a glass pipette is passed ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Galectin 1: A novel small protein therapy for Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: NIAMS

    DESCRIPTION provided by applicant Duchenne Muscular Dystrophy DMD is a fatal muscle disease affecting in every male births DMD results from mutations in the gene encoding the dystrophin a kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and a transmembrane protein complex called the dystrophin associated glycoprotein ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government